We have previously shown that constitutive phosphorylation of Met contributes to EGFR TKI resistance in breast cancer and that decreasing Met kinase activity, decreased EGFR tyrosine phosphorylation and proliferation in the presence of an EGFR tyrosine kinase inhibitor [7]. Here, MET is linked to breast carcinoma.